According to Yahoo!Finance, “VIVUS, Inc. (VVUS), a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.”
The Study of Failure
“The stock market indicators are seldom wrong, it’s the people who interpret them who make the mistakes (Russell, Richard. Dow Theory Letters. September 8, 1972. page 1.).”